TSB 9 W1

Drug Profile

TSB 9 W1

Alternative Names: IDS; TSB-9-W1

Latest Information Update: 23 Feb 2016

Price : $50

At a glance

  • Originator Taiwan Sunpan Biotechnology Development
  • Class Antineoplastics
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase Unknown Colorectal cancer

Most Recent Events

  • 04 Sep 2014 Investigation in Colorectal cancer (Second-line therapy or greater, Late-stage disease) in Taiwan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top